サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1511811

米国のヘモグロビン異常症市場規模、シェア、動向分析レポート：タイプ別、診断別、療法別、地域別、セグメント別予測、2024～2030年

U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 80 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.74円
米国のヘモグロビン異常症市場規模、シェア、動向分析レポート：タイプ別、診断別、療法別、地域別、セグメント別予測、2024～2030年
出版日: 2024年06月06日
発行: Grand View Research
ページ情報: 英文 80 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のヘモグロビン異常症市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国のヘモグロビン異常症市場規模は2030年までに68億5,000万米ドルに達し、2024年から2030年までのCAGRは12.5%で成長すると予測されています。

鎌状赤血球症やサラセミアなどのヘモグロビン異常症の有病率の上昇は、重要な市場促進要因です。遺伝子検査や出生前スクリーニングなどの診断技術の進歩により、ヘモグロビン異常症の早期発見が向上しています。さらに、遺伝子治療やCRISPR-Cas9のような遺伝子編集技術など、新たな治療選択肢に関する研究が進んでおり、将来的にはより効果的な治療が期待できます。

ヘモグロビン血症に対する認識を高めるための政府のイニシアティブの高まりや、罹患者のケアへのアクセスの改善は、市場を牽引する上で重要な役割を果たしています。研究開発への資金援助も、この分野の技術革新を加速させています。

製薬企業、研究機関、ヘルスケアプロバイダーの協力は、新しい治療法の開発を促進し、患者のケアを向上させる。各社の強みを生かしたパートナーシップは、医薬品開発を加速させ、治療成績を向上させることができます。

米国のヘモグロビン異常症市場レポート・ハイライト

  • 鎌状赤血球症は2023年に60.1%のシェアを占め、タイプ別セグメントを支配し、予測期間中最も速いCAGRで成長すると予測されます。この成長は、鎌状赤血球症（SCD）治療へのアクセス改善を推進するバイオ製薬企業や非営利団体のイニシアティブの高まりに起因しています。
  • 鎌状赤血球病診断分野は2023年に最大の市場を占めました。次世代シーケンシングや分子診断などの遺伝子検査法を含む進歩が、このセグメントの成長を促進しています。
  • 鎌状赤血球病治療分野は2023年に最大の市場を占めました。遺伝子異常の修正を目的とした遺伝子治療や標的治療など、革新的な治療法の承認拡大が市場成長を後押ししています。
  • 2022年4月、ゲノム医薬品のサンガモ・セラピューティクス社は、SAR445136鎌状赤血球症プログラムをサノフィ社からサンガモ社に移行することを発表しました。この移行は、鎌状赤血球症に対する遺伝子編集治療の開発における重要な一歩となります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のヘモグロビン異常症市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 米国のヘモグロビン異常症市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国のヘモグロビン異常症市場：タイプの推定・動向分析

  • 市場シェア、2023年と2030年
  • セグメントダッシュボード
  • タイプ別市場の見通し
  • 市場規模と予測および動向分析、2018年～2030年

第5章 米国のヘモグロビン異常症市場：診断の推定・動向分析

  • 市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 診断別市場の見通し
  • 市場規模と予測および動向分析、2018年～2030年

第6章 米国のヘモグロビン異常症市場：療法の推定・動向分析

  • 市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 療法別市場の見通し
  • 市場規模と予測および動向分析、2018年～2030年

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
  • 企業プロファイル
    • Sangamo Therapeutics, Inc.
    • Global Blood Therapeutics, Inc.
    • bluebird bio, Inc.
    • Emmaus Life Sciences Inc.
    • Pfizer, Inc.
    • Novartis AG
    • Prolong Pharmaceuticals, LLC
    • Bioverativ Inc.
    • Celgene Corp.
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. hemoglobinopathies market: market outlook
  • Fig. 9 U.S. hemoglobinopathies competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. hemoglobinopathies market driver impact
  • Fig. 15 U.S. hemoglobinopathies market restraint impact
  • Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
  • Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
  • Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
  • Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
  • Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
  • Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
  • Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
  • Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
  • Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
  • Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-295-9

U.S. Hemoglobinopathies Market Growth & Trends:

The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.

The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies' strengths can accelerate drug development and improve treatment outcomes.

U.S. Hemoglobinopathies Market Report Highlights:

  • Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.
  • The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.
  • The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.
  • In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Diagnosis
    • 1.2.3. Therapy
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Diagnosis outlook
    • 2.2.3. Therapy outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Hemoglobinopathies Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Hemoglobinopathies Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Thalassemia
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Sickle cell disease
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Hb variants
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis

  • 5.1. Diagnosis Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Thalassemia
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Alpha
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.2. Blood test
      • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.3. Genetic test
      • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.4. Prenatal genetic test
      • 5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.5. Pre-implantation genetic test
      • 5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.6. Electrophoresis
      • 5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.7. Others
      • 5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Beta
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.2. Blood test
      • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.3. Genetic test
      • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.4. Prenatal genetic test
      • 5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.5. Pre-implantation genetic test
      • 5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.6. Electrophoresis
      • 5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.7. Others
      • 5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Sickle cell disease
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Blood test
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Genetic test
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.4. Prenatal genetic test
      • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.5. Electrophoresis
      • 5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.6. Others
      • 5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hb variants
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.2. Blood test
      • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.3. Genetic test
      • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.4. Prenatal genetic test
      • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.5. Electrophoresis
      • 5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.6. Others
      • 5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis

  • 6.1. Therapy Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Thalassemia
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.2. Alpha
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.2.2. Blood transfusion
      • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.2.2. Iron chelation therapy
      • 6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.3. Bone marrow transplant
      • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.4. Others
      • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Beta
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.3.2. Blood transfusion
      • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.2. Iron chelation therapy
      • 6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.3. Bone marrow transplant
      • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.4. Others
      • 6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Sickle Cell Disease
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. Blood transfusion
      • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. Hydroxyurea
      • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Bone marrow transplant
      • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.5. Others
      • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. (Hb) Variants
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.2. Blood transfusion
      • 6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.3. Hydroxyurea
      • 6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.4. Bone marrow transplant
      • 6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.5. Others
      • 6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Sangamo Therapeutics, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Global Blood Therapeutics, Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. bluebird bio, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Emmaus Life Sciences Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Pfizer, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Prolong Pharmaceuticals, LLC
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Bioverativ Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Celgene Corp.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives